<ENAMEX TYPE="ORGANIZATION">Delmed Inc.</ENAMEX>'s top two officers resigned and were succeeded by executives of <ENAMEX TYPE="ORGANIZATION">Fresenius USA Inc.</ENAMEX> and its parent, <ENAMEX TYPE="ORGANIZATION">Fresenius AG</ENAMEX>, a major Delmed holder that has been negotiating to acquire a controlling stake.
In addition, <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX>, which makes and sells a dialysis solution used in treating kidney diseases, said negotiations about pricing had collapsed between it and a major distributor, <ENAMEX TYPE="ORGANIZATION">National Medical Care Inc.</ENAMEX>
<ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> said <ENAMEX TYPE="PERSON">Robert S. Ehrlich</ENAMEX> resigned as chairman, president and chief executive. Mr. <ENAMEX TYPE="PERSON">Ehrlich</ENAMEX> will continue as a director and a consultant. <ENAMEX TYPE="PERSON">Leslie I. Shapiro</ENAMEX>, chief operating officer and chief financial officer, also resigned, the company said.
Mr. <ENAMEX TYPE="PERSON">Ehrlich</ENAMEX> was succeeded as chairman by <ENAMEX TYPE="PERSON">Gerd Krick</ENAMEX>, a director of <ENAMEX TYPE="ORGANIZATION">Fresenius</ENAMEX>, a West German pharmaceutical concern. <ENAMEX TYPE="PERSON">Ben Lipps</ENAMEX>, president of <ENAMEX TYPE="ORGANIZATION">Fresenius USA</ENAMEX>, was named president, chief executive and chief operating officer.
None of the officials was available for comment.
In trading on the <ENAMEX TYPE="ORGANIZATION">American Stock Exchange</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> closed at 50 cents, down 6.25 cents.
<ENAMEX TYPE="ORGANIZATION">Fresenius</ENAMEX> owns about 42% of <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX>'s fully diluted common stock. The two companies have been discussing a transaction under which <ENAMEX TYPE="ORGANIZATION">Fresenius</ENAMEX> would buy <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> stock for cash to bring its beneficial ownership to between 70% and 80% of <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX>'s fully diluted common stock. The transaction also would combine <ENAMEX TYPE="ORGANIZATION">Fresenius USA</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX>.
Under the proposal, <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> would issue about 123.5 million additional <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> common shares to Fresenius at an average price of about 65 cents a share, though under no circumstances more than 75 cents a share.
Yesterday, <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> said it ``continues to explore the possibility of a combination with <ENAMEX TYPE="ORGANIZATION">Fresenius USA.</ENAMEX>'' It added that it is apparent that any terms of a combination ``would be substantially less favorable than those previously announced.''
While the discussions between <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">National Medical Care</ENAMEX> have been discontinued, <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> will continue to supply dialysis products through <ENAMEX TYPE="ORGANIZATION">National Medical</ENAMEX> after their exclusive agreement ends in March 1990, <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> said. In addition, <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> is exploring distribution arrangements with <ENAMEX TYPE="ORGANIZATION">Fresenius USA</ENAMEX>, <ENAMEX TYPE="ORGANIZATION">Delmed</ENAMEX> said.
